Savara Inc. (NASDAQ: SVRA) Is Getting Increasingly Hard To Ignore

DE Stock
DE Stock

BlackRock Fund Advisors recently announced the acquisition of new stake in Savara Inc. (NASDAQ:SVRA). The institutional investor has increased its shareholding in the Healthcare company by 19.76% to 2.51 million shares with purchase of 0.41 million shares. This fresh investment now brings its stake to 4.82% valued currently at $5.0 million. In addition, The Vanguard Group, Inc. raised its holdings by 0.4 million to 1.7 million shares. And AXA Investment Managers UK Ltd. has lifted its position by 5.31% or 71241.0 shares – to 1.41 million shares.

With over 1.63 million Savara Inc. (SVRA) shares trading Friday and a closing price of $1.42 on the day, the dollar volume was approximately $2.32 million. The shares have shown a negative weekly performance of -11.25% and its price on 08/28/20 gained nearly 1.43%. Currently, there are 58.86M common shares owned by the public and among those 45.46M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 3 analysts who have offered their price forecasts for SVRA have a consensus price objective of $4.83. The analysts have set the share’s price value over the next 12 months at a high of $7.00 and a low of $2.50 should the stock experience a downside. Incidentally, analysts’ outlook for the Savara Inc. stock is 2.20 for the next 12 months. But an upside of 79.71% will see the stock hit the forecast high price target while mean target price for the stock is $5.00.

Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.

The top 3 mutual fund holders in Savara Inc. are AXA Framlington Biotech Fund, Vanguard Total Stock Market Index, and iShares Russell 2000 ETF. AXA Framlington Biotech Fund owns 1.34 million shares of the company’s stock, all valued at over $2.67 million. iShares Russell 2000 ETF sold 44744.0 shares to bring its total holdings to over 0.96 million shares at a value of $1.9 million. iShares Russell 2000 ETF now owns shares totaling to 1.83% of the shares outstanding.

Shares of Savara Inc. (NASDAQ: SVRA) opened at $1.41, up $0.01 from a prior closing price of $1.40. However, the script later closed the day at $1.42, up 1.43%. The company’s stock has a 5-day price change of -11.25% and -41.32% over the past three months. SVRA shares are trading -68.30% year to date (YTD), with the 12-month market performance down to -38.79% lower. It has a 12-month low price of $0.69 and touched a high of $5.48 over the same period. Currently, 1.63 million shares have been traded, compared to an average intraday trading volume of 324.77K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -23.35%, -32.10%, and -37.14% respectively.

Institutional ownership of Savara Inc. (NASDAQ: SVRA) shares accounts for 46.10% of the company’s 58.86M shares outstanding. Mutual fund holders own 25.00%, while other institutional holders and individual stakeholders account for 6.37% and 12.60% respectively.

It has a market capitalization of $75.80M and a beta (3y monthly) value of 0.67. The earnings-per-share (ttm) stands at -$1.45. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.48% over the week and 7.17% over the month.

Analysts forecast that Savara Inc. (SVRA) will achieve an EPS of -$0.2 for the current quarter, -$0.2 for the next quarter and -$0.73 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.21 while analysts give the company a high EPS estimate of -$0.2. Comparatively, EPS for the current quarter was -$0.3 a year ago. Earnings per share for the fiscal year are expected to decrease by -5.70%, and 12.00% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate Savara Inc. (SVRA) as a “Moderate Buy” at a consensus score of 2.20. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 1 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the SVRA, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on June 13, 2019, with the firm’s price target at $22-$6. Ladenburg Thalmann coverage for the Savara Inc. (SVRA) stock in a research note released on June 13, 2019 offered a Neutral rating with a price target of $3. JMP Securities was of a view on June 13, 2019 that the stock is Mkt Perform, while ROTH Capital gave the stock Neutral rating on August 13, 2018, issuing a price target of $12. Ladenburg Thalmann on their part issued Buy rating on January 03, 2018.


Please enter your comment!
Please enter your name here